Human BioSystems
OTC Bulletin Board : HBSC

Human BioSystems

October 09, 2007 16:05 ET

HBS Cold Preservation Solution Article Published in the Current Issue of the Prestigious Journal of Investigative Surgery

PALO ALTO, CALIFORNIA--(Marketwire - Oct. 9, 2007) - Human BioSystems ("HBS" or "Company") (OTCBB:HBSC) a Silicon Valley-based bio-tech company specializing in the development of advanced organ, tissue and cellular preservation platforms and holder of five U.S. patents covering such technologies, announces publication of a professional paper describing its unique cold-storage preservation solution in the peer-reviewed Journal of Investigative Surgery (2007;20:257-263).

In this study utilizing a rat kidney transplant model, the HBS cold-preservation solution was compared head-to-head against other preservation solutions considered to be the current 'gold standards' in the field. The HBS cold storage solution was designed to provide superior metabolic support for organs undergoing transplantation.

Luis H. Toledo, M.D., Ph.D., a recognized transplantation surgeon and organ preservation scientist, and Director of the HBS Research Laboratory, stated "The HBS solution out-performed the other solutions (HTK and UWS) in terms of the HBS Reperfusion Damage Index (RDI), chemical indicators of kidney function, and microscopic appearance. Survival was also markedly improved in the HBS group of animals. At seven days there was 80% survival compared to 20% and 50% survival in the competing groups."

Based on these impressive findings Dr. Fernando Lopez-Neblina, the co-author of the peer-reviewed paper and HBS Senior Research Scientist, said "The HBS preservation solution offers a new alternative for kidney cold storage with significantly improved results when compared with the HTK and UWS solutions."

Dr. David Winter, President of HBS, said "The publication of these scientific results in the respected Journal of Investigative Surgery provides credibility for our research program and highlights the progress we have achieved in advancing the science of the biologic preservation of organs. We are in discussion with transplant surgeons in other centers to extend the current results in large animal studies."

Harry Masuda, CEO of HBS, noted "These findings propel us toward our ultimate goal of establishing market share in the transplantation solution arena. If these results hold up in large animal studies, we feel they would justify extensive human clinical studies, the next step in getting to market."

Reprint requests may be directed to Dr. Luis Toledo at email:, or by contacting the Company.

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

Contact Information